Communiqués de presse Eli Lilly — News Releases Santé & sciences de la vie — Flux RSS et veille en direct
PPN World suit le flux RSS de Eli Lilly — News Releases en temps réel — 5 communiqués indexés au cours des 30 derniers jours, le plus récent est arrivé il y a 2 j. Suivez-le avec alertes sur recherches enregistrées, résumés IA et recherche plein texte, ou branchez l'URL RSS ci-dessous dans votre propre lecteur.
URL du flux RSS de Eli Lilly — News Releases
https://investor.lilly.com/rss/news-releases.xml?items=10À propos de ce fil
Eli Lilly — News Releases fait partie des 1000+ fils de presse que PPN World surveille en continu — un fil en anglais axé sur le secteur Santé & sciences de la vie, classé sous « États-Unis » dans notre index par pays. Chaque communiqué est dédupliqué, géolocalisé et enrichi d'un résumé IA, et vous pouvez y attacher des alertes sur recherches enregistrées. Eli Lilly — News Releases est un fil spécialisé à faible volume — 5 communiqués dans les 30 derniers jours : le genre de source qui mérite une alerte plutôt qu'un défilement.
Comment suivre les communiqués de Eli Lilly — News Releases
- Copiez l'URL du flux RSS de Eli Lilly — News Releases affichée ci-dessus.
- Collez-la dans n'importe quel lecteur RSS (Feedly, Inoreader, NetNewsWire…) pour recevoir le flux brut.
- Ou suivez Eli Lilly — News Releases dans PPN World pour ajouter déduplication, alertes sur recherches enregistrées et résumés IA sur les 1000+ fils.
Derniers communiqués de Eli Lilly — News Releases
- Lilly confirms date and conference call for second-quarter 2026 financial results announcementil y a 2 j
INDIANAPOLIS, July 22, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2026 financial results on August 5, 2026. Lilly will also conduct a conference call that…
- Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditionsil y a 9 j
AtaiBeckley's lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression Acquisition expands Lilly's neuroscience pipeline to address some of the most challenging…
- Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatmentil y a 16 j
Analyses across Kisunla (donanemab-azbt) trials providing further insights into the benefit-risk profile from long-term extension data New data compares the diagnostic performance of P-tau217 blood te…
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapyil y a 29 j
The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society of Hematology Annual Meeting and published in The Jo…
- Lilly launches “The Memory Radio Station” across Europe, inviting the public to visually reconstruct fading memories through GenAIil y a 29 j
New multi-country campaign launches in Geneva alongside the European Academy of Neurology Congress GENEVA, SWITZERLAND, June 26, 2026 -- Today, Eli Lilly and Company (NYSE: LLY) launches The Memory Ra…
- What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight managementil y a 30 j
A new Medicare pathway, the Medicare GLP-1 Bridge program, makes Lilly's obesity medicines – a daily pill or the number 1 most prescribed injectable – accessible to eligible Medicare Part D patients b…
- Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disordersil y a 30 j
INDIANAPOLIS, June 24, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Centessa Pharmaceuticals plc. Centessa is a clinical-stage…
- Lilly declares third-quarter 2026 dividendil y a 32 j
INDIANAPOLIS, June 22, 2026 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2026 of $1.73 per share on outstanding common s…
- Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLLil y a 41 j
BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients previously treated with a covalent BTK inhibitor…
Les plus récents communiqués de ce fil défilent en direct pour les membres PPN World.